Every Form 4 that BioCryst Pharmaceuticals Inc (BCRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCRX filings page.
BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. Stonehouse Jon P reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC (BCRX) director Jon P. Stonehouse received a grant of 644 shares of Common Stock on August 31, 2026, at a value of $9.70 per share. The shares were issued in lieu of 50% of a quarterly cash Board Member retainer of $12,500. Following this award, he holds 1,340,419 shares directly, plus 40,000 shares held indirectly in each of two irrevocable trusts for Caroline and Samuel Stonehouse. No Rule 10b5‑1 trading plan is reported.
BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. Milne Jill C. reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Jill C. Milne received a grant of 1,288 shares of Common Stock on August 31, 2026, as a board compensation award. The shares were issued in lieu of a $12,500 quarterly cash Board Member retainer, bringing her directly held stake to 33,226 shares. No Rule 10b5-1 trading plan is reported for this transaction.
BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Vincent Milano received an award of 1,159 shares of Common Stock on August 31, 2026. These shares were issued in lieu of 50% of his quarterly Board Chair cash retainer of $22,500, equating to a value of $9.70 per share. Following this grant, Milano directly holds 109,642 shares of Biocryst common stock. No transactions were reported under a Rule 10b5-1 trading plan.
BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC (BCRX) director Amy E. McKee received a grant of 644 shares of Common Stock on August 31, 2026, valued at $9.70 per share. The shares were issued in lieu of 50% of her $12,500 quarterly Board member cash retainer, bringing her direct holdings to 47,821 shares. No Rule 10b5-1 trading plan is reported.
BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Steven Frank received a grant of 1,288 shares of Common Stock on August 31, 2026 as a grant/award acquisition. The shares were issued at $9.70 per share in lieu of a $12,500 quarterly cash Board Member retainer, bringing his directly held stake to 36,747 shares. No Rule 10b5-1 trading plan is reported for this transaction.
BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received equity awards as part of non‑employee director compensation. She was granted 15,294 shares of Common Stock as Restricted Stock Units that will vest on the first anniversary of the June 11, 2026 grant date.
She also received an automatic grant of options to purchase 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable until June 11, 2036. Following the RSU grant, she holds 31,938 Common Stock shares directly. These are compensation-related awards rather than open-market purchases.
BIOCRYST PHARMACEUTICALS INC director Steven K. Galson reported equity awards and updated holdings. He received 15,294 shares of Common Stock as a grant of Restricted Stock Units under the company’s Non-Employee Director Compensation Policy, with these units scheduled to vest on the first anniversary of the grant date.
He also received an automatic stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable from June 11, 2027 and expiring June 11, 2036. Following these awards, he holds 27,794 Common shares directly and 58,371 Common shares indirectly through a living trust. The filing reflects compensation-related grants rather than open-market purchases or sales.
BIOCRYST PHARMACEUTICALS director Alan G. Levin received equity awards as part of non-employee director compensation. He was granted 15,294 shares of Common Stock as Restricted Stock Units that will vest on the first anniversary of the grant date. He also received an automatic stock option grant for 33,540 shares of Common Stock at an exercise price of $8.5000 per share, expiring on June 11, 2036. Following these awards, he directly holds 79,565 shares of Common Stock.
BIOCRYST PHARMACEUTICALS INC director equity awards: Director Steven Frank received a grant of 15,294 shares of Common Stock as Restricted Stock Units under the company’s Non-Employee Director Compensation Policy. These RSUs will vest on the first anniversary of the June 11, 2026 grant date.
Frank also received an automatic non-employee director stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable from June 11, 2027 and expiring June 11, 2036. After these awards, he directly holds 35,459 shares of Common Stock.
BioCryst Pharmaceuticals director Machelle Sanders received new equity awards consisting of restricted stock units and stock options. She was granted 15,294 shares of Common Stock as Restricted Stock Units under the company’s Non-Employee Director Compensation Policy, which will vest on the first anniversary of the grant date.
She also received an automatic stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. After these awards, she directly holds 45,936 shares of Common Stock. These are compensation-related grants, not open-market purchases or sales.
BIOCRYST PHARMACEUTICALS INC director Vincent Milano reported equity compensation awards rather than open-market trades. He received 15,294 shares of Common Stock as a grant, increasing his directly held stake to 108,483 shares. These were granted at no cash purchase price as part of his director compensation.
Milano was also granted an Automatic Stock Option for 33,540 shares of Common Stock with a conversion or exercise price of $8.50 per share. According to the company’s Non-Employee Director Compensation Policy, the Restricted Stock Units vest on the first anniversary of the grant date, and the stock options expire in 2036, reflecting routine, policy-based director compensation.
BioCryst Pharmaceuticals director Jon P. Stonehouse reported routine equity compensation grants. He received 15,294 shares of Common Stock as a grant, increasing his direct holdings to 1,339,775 shares. These shares were granted at no cash cost as part of his non-employee director compensation.
He was also granted an Automatic Stock Option for 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. Footnotes explain these are automatic non-employee director grants of Restricted Stock Units and stock options under BioCryst’s Director Compensation Policy. Two family irrevocable trusts associated with his wife each report indirect holdings of 40,000 Common Stock shares.
BioCryst Pharmaceuticals director Amy E. McKee received equity compensation awards. On the grant date, she acquired 15,294 shares of common stock through a restricted stock unit grant under the company’s Non-Employee Director Compensation Policy. Following this grant, she directly holds 47,177 common shares.
She was also granted an automatic stock option covering 33,540 shares of common stock at an exercise price of $8.50 per share, exercisable until June 11, 2036. The restricted stock units will vest on the first anniversary of the grant date, aligning her compensation with long-term shareholder interests.
BIOCRYST PHARMACEUTICALS INC director Theresa Heggie reported equity awards received as part of non-employee director compensation. She acquired 15,294 shares of Common Stock through a grant of Restricted Stock Units that will vest on the first anniversary of the grant date. She also received an automatic stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. Following these awards, she directly holds 80,646 shares of Common Stock. These awards were made under the company’s Non-Employee Director Compensation Policy and represent routine compensation, not open-market buying or selling.
BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received a stock grant as part of her board compensation. On May 29, 2026, she acquired 1,262 shares of common stock valued at $8.91 per share. The filing states these shares were issued in lieu of a quarterly cash board member retainer of $11,250.
After this award, Milne directly holds 16,644 shares of BioCryst common stock. This is a routine, non-market transaction reflecting compensation paid in equity instead of cash, rather than an open-market purchase or sale.
Stonehouse Jon P reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Jon P. Stonehouse reported receiving 631 shares of Common Stock on May 29, 2026. These shares were issued in lieu of 50% of his quarterly Board member cash retainer of $11,250 at a price of $8.91 per share.
After this stock-based retainer, Stonehouse directly holds 1,324,481 shares of Common Stock. The filing also lists 40,000 shares held in the Samuel Stonehouse Irrevocable Trust and 40,000 shares in the Caroline Stonehouse Irrevocable Trust, reported as indirect ownership through his wife as co‑trustee.
McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Amy E. McKee reported receiving a grant of 631 shares of Common Stock on May 29, 2026 at a reference price of $8.91 per share. The shares were issued to her in lieu of 50% of a quarterly Board member cash retainer of $11,250. Following this compensation-related award, she directly holds 31,883 shares of the company’s Common Stock.
MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Vincent Milano reported receiving 1,122 shares of Common Stock on May 29, 2026. These shares were granted as compensation, issued in lieu of 50% of his quarterly cash Board Chair retainer of $20,000. After this grant, he directly holds 93,189 shares of the company’s common stock. This is a routine, non-market award rather than an open-market purchase.
Frank Steven reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Steven Frank received a stock award instead of cash compensation. He was granted 1,262 shares of common stock at a reference value of $8.91 per share on May 29, 2026, issued in lieu of a $11,250 quarterly board cash retainer. After this grant, he directly holds 20,165 shares of BIOCRYST common stock. This is a routine, compensation-related equity award rather than an open-market purchase.
BIOCRYST PHARMACEUTICALS INC director Amy E. McKee sold 11,180 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $8.97 per share, with individual trade prices ranging from $8.96 to $8.985. Following the sale, she directly holds 31,252 shares of the company’s stock.
BIOCRYST PHARMACEUTICALS INC Chief Legal Officer Alane P. Barnes exercised employee stock options for 62,500 shares of common stock at $5.04 per share and sold 62,500 shares in an open-market transaction at $9.54 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan and is described as automatic, rather than a discretionary trade. After these transactions, Barnes directly holds 400,703 shares of Biocryst common stock.
BioCryst Pharmaceuticals Chief R&D Officer Sandeep Menon received equity grants as part of his compensation. On April 6, 2026, he was granted 441,350 employee stock options for common stock at an exercise price of $9.47 per share, expiring in 2036.
He also received an inducement grant of 205,150 restricted stock units of common stock. Both the RSUs and the options vest or become exercisable in equal 25% installments on each of the first, second, third and fourth anniversaries of the grant date, aligning his incentives with longer-term company performance rather than reflecting open-market trading.
BIOCRYST PHARMACEUTICALS INC director Theresa Heggie exercised stock options and sold shares on March 20, 2026. She exercised options for 49,933 shares of Common Stock at an exercise price of $6.30 per share and acquired the same number of shares.
She then sold 49,933 Common shares in an open-market transaction at a weighted average price of $10.11 per share, in multiple trades between $10.09 and $10.14. Following these transactions, she directly holds 65,352 shares of Common Stock.
BioCryst Pharmaceuticals Chief Legal Officer Alane P. Barnes exercised stock options and sold shares in a planned transaction. On March 16, 2026, she exercised options for 150,000 shares of common stock at an exercise price of $5.51 per share.
The same day, she sold 150,000 shares of common stock at a weighted average price of $9.15 per share, with individual sale prices ranging from $8.95 to $9.57. After these transactions, she directly owned 400,703 shares of common stock. The filing states the sale was made automatically under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025, indicating it was not a discretionary trade.
BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received additional company stock as part of her board compensation. On February 27, 2026, she acquired 528 shares of Common Stock at a price of $8.75 per share through a grant classified as a board retainer in stock rather than cash. After this award, she directly owns 15,382 Common Stock shares. A footnote explains the shares were issued in lieu of 100% of her prorated quarterly cash board member retainer of $4,625, meaning the company paid this portion of her board fees in stock instead of cash.
BIOCRYST PHARMACEUTICALS INC director Jon P. Stonehouse reported several equity transactions. On March 2, 2026, he exercised an employee stock option for 305,995 shares of common stock at an exercise price of $3.22 per share, converting the derivative into common stock.
That same day, he reported a disposition of 305,995 common shares at a weighted average price of $8.64 per share; a footnote states these shares were sold in multiple transactions between $8.54 and $8.81 under a pre-established Rule 10b5-1 trading plan, and the transaction occurred automatically. After this, his direct common stock holdings were 1,323,850 shares.
On February 27, 2026, he also acquired 421 common shares at $8.75 per share, issued in lieu of 50% of a prorated quarterly cash board retainer of $7,375. In addition, there are 40,000 common shares held indirectly in each of two irrevocable trusts, where his wife serves as co-trustee.
MILANO VINCENT reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Vincent Milano received 848 shares of Common Stock as a compensation award. The shares were issued at a reference price of $8.75 per share, bringing his directly held total to 92,067 shares after the transaction.
The footnote explains that these shares were issued in lieu of 50% of his quarterly cash Board member retainer of $11,250 and, effective January 23, 2026, in lieu of 50% of the quarterly cash Board Chair retainer of $20,000. This represents routine equity-based director compensation rather than an open-market purchase or sale.
Frank Steven reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Steven Frank received an equity grant of 1,285 shares of Common Stock on February 27, 2026. The shares were issued in lieu of 100% of his quarterly cash board member retainer of $11,250, reflecting a stock-based compensation choice rather than a market purchase. Following this award, he directly owns 18,903 shares of the company’s common stock.
McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Amy E. McKee reported receiving an award of 642 shares of common stock on February 27, 2026. The shares were issued in lieu of 50% of a quarterly cash board retainer of $11,250, bringing her direct holdings to 42,432 shares.
BioCryst Pharmaceuticals director Jill C. Milne reported new equity holdings following a merger and standard director compensation grants. On 01/23/2026 she received 2,582 shares of BioCryst common stock in exchange for 4,377 Astria Therapeutics shares under a merger where each Astria share was converted into 0.59 BioCryst share plus $8.55 in cash.
She also acquired 12,272 restricted stock units as an automatic non-employee director grant that will vest in three equal annual installments starting one year after grant. In addition, she received an automatic stock option grant for 26,684 shares at an exercise price of $6.79, vesting 1/36 per month over three years and expiring on 01/23/2036.
BioCryst Pharmaceuticals reported an insider equity transaction by an officer serving as President and CCO. On 12/12/2025, 8,181 shares of common stock were withheld by the company at $7.57 per share to cover required tax withholding tied to the vesting of previously granted restricted stock units.
The explanation clarifies that this withholding is for tax purposes and does not represent a sale by the officer. Following this transaction, the officer directly beneficially owns 418,827 shares of BioCryst Pharmaceuticals common stock.
BioCryst Pharmaceuticals Chief Legal Officer Alane P. Barnes reported two equity transactions in December 2025. On December 12, 8,540 shares of common stock were withheld at $7.57 per share to satisfy required tax withholding tied to vesting restricted stock units, and this is explicitly described as not representing a sale by Barnes.
On December 15, Barnes sold 21,210 shares of common stock at $7.65 per share under a trading plan adopted on August 13, 2025 in accordance with Rule 10b5-1, with the transaction occurring automatically rather than as a discretionary trade. Following these transactions, Barnes directly beneficially owned 315,726 shares of BioCryst common stock.
BioCryst Pharmaceuticals reported that a director who also serves as Chief Executive Officer had 27,368 shares of common stock withheld on December 12, 2025 to satisfy required tax withholding obligations tied to the vesting of previously granted restricted stock units at a price of $7.57 per share.
After this transaction, the insider beneficially owns 1,405,222 shares directly, plus 30,000 shares held in each of two irrevocable trusts for which the insider’s spouse serves as co‑trustee.
The company notes that this tax withholding does not represent an open‑market sale by the reporting person.
BioCryst Pharmaceuticals, Inc. (BCRX) reported an insider share sale by a director. On 11/13/2025, the reporting person sold 9,600 shares of common stock at $7.14 per share in an open market sale, coded "S" for sale. After this transaction, the director beneficially owned 30,642 shares of BioCryst common stock in direct ownership form.
The shares were sold under a pre-arranged trading plan adopted on August 14, 2025 pursuant to Rule 10b5-1. This means the sale occurred automatically according to the plan’s terms rather than as a new discretionary trading decision by the director.